Recent updates from financial analysts have provided new insights into the outlook for Phathom Pharmaceuticals (NASDAQ: PHAT). On October 31, 2025, analysts at Craig Hallum reaffirmed their “buy” rating for the company, setting a price target of $22.00 per share.
On the same day, HC Wainwright also increased its price target for Phathom Pharmaceuticals from $20.00, reflecting a positive sentiment towards the company”s future prospects. This biopharmaceutical firm is dedicated to developing and commercializing innovative treatments for gastrointestinal diseases.
Phathom Pharmaceuticals holds rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. As the company progresses in its development efforts, these analyst ratings may influence investor confidence and market performance.
For those interested in staying informed about Phathom Pharmaceuticals and related news, a concise daily summary of the latest developments and analyst ratings is available through MarketBeat.com“s free daily email newsletter. By entering an email address, subscribers can receive timely updates on the company and its market activities.
